MX2007003272A - Tratamiento de la osteoporosis inducida por medio de la falta de androgenos. - Google Patents
Tratamiento de la osteoporosis inducida por medio de la falta de androgenos.Info
- Publication number
- MX2007003272A MX2007003272A MX2007003272A MX2007003272A MX2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A MX 2007003272 A MX2007003272 A MX 2007003272A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen
- induced osteoporosis
- deprivation induced
- treatment
- incidence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion proporciona metodos para reducir la incidencia de, inhibir, suprimir y tratar la osteoporosis inducida por la falta de androgenos, las fracturas de huesos y/o la perdida de la densidad osea (BMD) en hombres mineral osea (BMD) en hombres que tengan cancer de prostata, que consiste en administrar a un humano masculino que tenga cancer de prostata un toremifeno y/o sus analogos, derivados, isomeros, metabolitos, sales farmaceuticamente aceptables, producto farmaceutico, hidrato. N-oxido o un combinacion del mismo. La presente invencion tambien proporciona metodos para tratar, prevenir, suprimir, inhibir, o reducir a incidencia de bochornos, ginecomastia y/o la perdida de cabello en un sujeto que lo presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/944,465 US20050080143A1 (en) | 2001-11-29 | 2004-09-20 | Treatment of androgen-deprivation induced osteoporosis |
PCT/US2005/032998 WO2006033979A1 (en) | 2004-09-20 | 2005-09-19 | Treatment of androgen - deprivation induced osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007003272A true MX2007003272A (es) | 2007-06-05 |
Family
ID=36090335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007003272A MX2007003272A (es) | 2004-09-20 | 2005-09-19 | Tratamiento de la osteoporosis inducida por medio de la falta de androgenos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050080143A1 (es) |
EP (2) | EP1935415A3 (es) |
JP (2) | JP2008513469A (es) |
KR (1) | KR20070059167A (es) |
CN (2) | CN101961327A (es) |
AU (1) | AU2005287113B2 (es) |
BR (1) | BRPI0515668A (es) |
CA (1) | CA2581159A1 (es) |
EA (1) | EA014309B1 (es) |
IL (1) | IL182091A0 (es) |
MX (1) | MX2007003272A (es) |
WO (1) | WO2006033979A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2464203A (en) | 1943-05-21 | 1949-03-15 | Boots Pure Drug Co Ltd | Manufacture of dienoestrol |
US2465505A (en) | 1944-12-05 | 1949-03-29 | Hoffmann La Roche | Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4 |
US2914562A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Amine derivatives of triphenylethanol |
GB8508404D0 (en) * | 1985-03-30 | 1985-05-09 | Baylor College Medicine | Therapeutic compositions |
US4897254A (en) * | 1984-09-21 | 1990-01-30 | The Dow Chemical Company | Radioactive compositions for the treatment of calcific tumors |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
FR2578113B1 (fr) * | 1985-02-25 | 1988-04-15 | Merlin Gerin | Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique |
US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
CA2062792C (en) * | 1989-07-07 | 2006-03-21 | Fernard Labrie | Treatment of androgen-related diseases |
US5153622A (en) * | 1989-08-03 | 1992-10-06 | Asahi Kogaku Kogyo Kabushiki Kaisha | Pressure alarm for water-sealed camera |
JPH06287885A (ja) * | 1991-04-15 | 1994-10-11 | Yamauchi Corp | 脱水プレス用エンドレスベルト |
GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
TW303299B (es) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
TW403738B (en) * | 1994-08-12 | 2000-09-01 | Hoffmann La Roche | Tricyclic pyrazole derivatives |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
JP2000506738A (ja) * | 1996-03-18 | 2000-06-06 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 細胞付着および機能を強化するための生物活性材料基質 |
GB9712086D0 (en) * | 1997-06-10 | 1997-08-13 | Bp Chem Int Ltd | Process for preparing polyketones |
US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
DK1003496T3 (da) * | 1998-05-07 | 2005-04-04 | Univ Tennessee Res Corp | Lægemiddel til behandling af prostatisk intraepitelial neoplasi |
US6413535B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
EP1102755B1 (en) * | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
US6165504A (en) * | 1998-09-23 | 2000-12-26 | Barr Laboratories, Inc. | Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients |
US6258802B1 (en) * | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
WO2001054699A1 (en) * | 2000-01-28 | 2001-08-02 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
US6855703B1 (en) * | 2000-03-10 | 2005-02-15 | Endeavor Pharmaceuticals | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
GB0012291D0 (en) * | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
JP2003534375A (ja) * | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
IL152719A0 (en) * | 2000-06-28 | 2003-06-24 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification |
US20030114420A1 (en) * | 2000-06-28 | 2003-06-19 | Salvati Mark E. | Fused cyclic modulators of nuclear hormone receptor function |
EP1324754A1 (en) * | 2000-07-05 | 2003-07-09 | AstraZeneca AB | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
EP1210951B1 (en) * | 2000-11-30 | 2005-02-02 | Pfizer Products Inc. | Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone |
US6413633B1 (en) * | 2001-04-18 | 2002-07-02 | Francis Patrick McCullough | Activated biregional fiber(s) |
JP2004530684A (ja) * | 2001-05-10 | 2004-10-07 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
CA2447518A1 (en) * | 2001-05-17 | 2002-11-21 | Immunex Corporation | Therapeutic use of rank antagonists |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
EA200400744A1 (ru) * | 2001-11-29 | 2005-02-24 | Джи Ти Икс, ИНК. | Предупреждение и лечение остеопороза, вызванного депривацией андрогенов |
US20040152733A1 (en) * | 2002-03-15 | 2004-08-05 | Wallace Owen Brendan | Duloxetine for treatment of hot flashes |
MXPA05001705A (es) * | 2002-08-14 | 2005-04-19 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para el tratamiento de sofocos. |
US6838684B2 (en) * | 2002-08-23 | 2005-01-04 | Asml Netherlands B.V. | Lithographic projection apparatus and particle barrier for use therein |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
EP1617859A1 (en) * | 2003-04-30 | 2006-01-25 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
US7048210B2 (en) * | 2003-05-21 | 2006-05-23 | Frank Clark | Showerhead with grooved water release ducts |
US20060019989A1 (en) * | 2004-07-21 | 2006-01-26 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof |
-
2004
- 2004-09-20 US US10/944,465 patent/US20050080143A1/en not_active Abandoned
-
2005
- 2005-09-19 KR KR1020077009072A patent/KR20070059167A/ko not_active Application Discontinuation
- 2005-09-19 CN CN2010105026847A patent/CN101961327A/zh active Pending
- 2005-09-19 CN CN2005800390976A patent/CN101056621B/zh not_active Expired - Fee Related
- 2005-09-19 JP JP2007532470A patent/JP2008513469A/ja active Pending
- 2005-09-19 EP EP08153021A patent/EP1935415A3/en not_active Withdrawn
- 2005-09-19 EP EP05797480A patent/EP1796643A4/en not_active Withdrawn
- 2005-09-19 WO PCT/US2005/032998 patent/WO2006033979A1/en active Application Filing
- 2005-09-19 MX MX2007003272A patent/MX2007003272A/es unknown
- 2005-09-19 EA EA200700690A patent/EA014309B1/ru not_active IP Right Cessation
- 2005-09-19 BR BRPI0515668-8A patent/BRPI0515668A/pt not_active IP Right Cessation
- 2005-09-19 CA CA002581159A patent/CA2581159A1/en not_active Abandoned
- 2005-09-19 AU AU2005287113A patent/AU2005287113B2/en not_active Expired - Fee Related
-
2007
- 2007-03-21 IL IL182091A patent/IL182091A0/en unknown
-
2008
- 2008-09-19 JP JP2008240566A patent/JP2009029823A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1796643A4 (en) | 2009-09-09 |
EP1796643A1 (en) | 2007-06-20 |
KR20070059167A (ko) | 2007-06-11 |
CN101056621B (zh) | 2010-11-10 |
CA2581159A1 (en) | 2006-03-30 |
IL182091A0 (en) | 2011-08-01 |
AU2005287113B2 (en) | 2011-06-16 |
EA200700690A1 (ru) | 2007-10-26 |
JP2008513469A (ja) | 2008-05-01 |
BRPI0515668A (pt) | 2008-07-29 |
CN101961327A (zh) | 2011-02-02 |
EA014309B1 (ru) | 2010-10-29 |
WO2006033979A1 (en) | 2006-03-30 |
EP1935415A3 (en) | 2009-09-16 |
AU2005287113A1 (en) | 2006-03-30 |
JP2009029823A (ja) | 2009-02-12 |
CN101056621A (zh) | 2007-10-17 |
US20050080143A1 (en) | 2005-04-14 |
EP1935415A2 (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003047504A3 (en) | Prevention and treatment of androgen-deprivation induced osteoporosis | |
EP1816996A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER | |
AU2003278775A8 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
IL179515A0 (en) | Method of administering and using vegf inhibitors for the treatment of human cancer | |
IL175568A (en) | Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases | |
AU2003253877A1 (en) | Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
EP2165715A4 (en) | THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER | |
MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
EP2136814A4 (en) | MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
MX2007003272A (es) | Tratamiento de la osteoporosis inducida por medio de la falta de androgenos. | |
MX335951B (es) | Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades. | |
MX2011011687A (es) | Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer. | |
MX2017000886A (es) | Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica. | |
IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
EP1937711A4 (en) | EPITOPES, COMBINED EPITOPES, USE OF EPITOPES OR COMBINATIONS THEREOF, COMPOSITION, USE OF THE COMPOSITION, PROPHYLACTIC ANTI-HIV-I VACCINES, THERAPEUTIC VACCINES, METHOD FOR IDENTIFYING EPITOPES AND METHODS OF TREATMENT AND PREVENTION | |
SG153661A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
IL166062A0 (en) | Compositions and methods for therapeutic treatment | |
MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. | |
TWI368518B (en) | Use of a medicament for treating and/or controlling local recurrence of solid tumours during and after surgery,and a kit comprising said medicament | |
MXPA04009012A (es) | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. | |
MXPA05004920A (es) | Combinacion que comprende un inhibidor cdk y cisplatin. | |
EP1583543A4 (en) | METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA |